Oppenheimer Asset Management Inc. Makes New Investment in Ascendis Pharma A/S $ASND

Oppenheimer Asset Management Inc. bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,441 shares of the biotechnology company’s stock, valued at approximately $883,000.

A number of other hedge funds have also modified their holdings of ASND. Braun Stacey Associates Inc. acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth $18,678,000. Sector Gamma AS boosted its holdings in Ascendis Pharma A/S by 43.1% in the third quarter. Sector Gamma AS now owns 24,327 shares of the biotechnology company’s stock worth $4,836,000 after purchasing an additional 7,327 shares in the last quarter. Principal Financial Group Inc. increased its position in Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock worth $157,791,000 after buying an additional 765,561 shares during the last quarter. Calamos Advisors LLC bought a new position in Ascendis Pharma A/S during the third quarter valued at about $1,282,000. Finally, Allianz Asset Management GmbH lifted its position in shares of Ascendis Pharma A/S by 144.7% in the second quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 5,500 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Oppenheimer boosted their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research note on Thursday. Stifel Nicolaus set a $325.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday. Finally, Wells Fargo & Company lifted their target price on shares of Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $284.00.

Ascendis Pharma A/S Trading Down 0.8%

Shares of ASND stock opened at $216.32 on Friday. The firm has a market capitalization of $13.41 billion, a P/E ratio of -49.16 and a beta of 0.44. Ascendis Pharma A/S has a 1 year low of $124.06 and a 1 year high of $242.00. The firm’s fifty day simple moving average is $214.86 and its 200 day simple moving average is $205.14.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $285.35 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Key Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Management flagged growth momentum on the Q4 call and highlighted strong YORVIPATH uptake — a driver for near-term revenue expansion. Ascendis Pharma FY 2025 Results: More Than A Takeover Story
• Positive Sentiment: Quarterly revenue slightly beat consensus (company reported ~$290M vs. ~285M expected), supported by YORVIPATH sales highlighted in the earnings summary. Earnings Call Highlights
• Positive Sentiment: Wedbush raised its price target to $273 and kept an outperform stance — a meaningful analyst upgrade that implies upside from current levels. Wedbush Price Target Raise
• Positive Sentiment: Street coverage remains constructive overall — brokerages’ consensus is an average “Buy”, supporting near-term investor interest. Brokerage Ratings
• Neutral Sentiment: Independent investor outlets are comparing ASND to peers (Ionis) and discussing momentum; these pieces provide context but aren’t new company catalysts. AAII Comparison
• Neutral Sentiment: Full earnings-call transcripts and analyst writeups are available for deeper read — useful for conviction but not immediate market-moving on their own. Earnings Call Transcript
• Neutral Sentiment: Reported short-interest data in recent releases show zeros and a days-to-cover of 0.0 — likely a reporting/data anomaly rather than a real change in short exposure; monitor official filings for clarity.
• Negative Sentiment: EPS missed substantially: ASND reported a ($0.64) loss vs. consensus (~$-0.06), which is weighing on near-term sentiment despite the revenue beat. Earnings Summary / EPS Miss
• Negative Sentiment: Sector competition: news that BridgeBio’s moves are reshaping the achondroplasia landscape pressured shares across peers (BioMarin, Ascendis) as investors reassess competitive risk. BridgeBio Competitive News

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.